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Abstract 
Introduction. The significance of over-expression of epidermal growth factor receptor 
(EGFR) in pancreatic carcinoma is unclear. In this study, we examined the association 
between EGFR over-expression (membranous and cytoplasmic), the associated 
histopathologic features and clinical outcomes in post resection pancreatic cancer 
patients. 
 
Methods. EGFR expression was determined immunohistochemically in 90 patients who 
underwent resection for pancreatic cancer. Cytoplasmic expression was considered 
positive if EGFR expression was seen in the cytoplasm in ≥10% of cells. Cell membrane 
staining was scored from 0 to 3+, with 2+ and 3+ being considered as membrane over-
expression. Overall survival and progression free survival were calculated using the 
Kaplan-Meier method and survival curves were compared by the log-rank test. 
 
Results. Out of 90 patients, 51 (57%) and 74 (68%) patients had membrane and 
cytoplasmic EGFR over-expression respectively. There was a statistically significant 
correlation between cell membrane EGFR over-expression and lymph node positivity 
(p=0.03). Patients with membrane EGFR over-expression had a shorter median 
progression free survival (10.7 vs. 17.0 months, p=0.02) and overall survival (15.9 
months v 25.3 months, p=0.17). Cytoplasmic EFGR over-expression was not 
significantly associated with recurrence or survival. 
 
Conclusions. Membrane EGFR over-expression in resected pancreatic cancer patients 
was associated with worse clinical outcomes than non over-expression. 
 
 
Introduction 
Pancreatic cancer is the fourth leading cause of cancer death in United States with 36,800 
deaths and 43,140 incident cases estimated in 2010.{{193 Jemal,A. 2010}} Despite 
therapy, the 5-year relative survival rate is approximately 6%. Due to relative lack of 
early disease-specific symptoms, only a minority of the patients present with surgically 
resectable disease. Even in patients who undergo pancreatectomy, the majority of the 
patients develop recurrence with the 5-year overall survival of only 22.5%.{{193 
Jemal,A. 2010}} Various genetic and molecular alterations are being investigated to 
understand the basis of the disease aggressiveness. 
 Epidermal growth factor receptor (EGFR) is a 170 kDa protein belonging to ErbB 
family of transmembrane tyrosine kinase growth factor receptors.{{199 Lemoine,N.R. 
1992}} It is overexpressed in wide variety of solid tumors including breast, colon, lung 
and prostate cancer.{{198 Nicholson,R.I. 2001}} Activation of EGFR in tumors results 
in increased cell proliferation, reduced apoptosis, increased angiogenesis, increased 
motility, invasion and metastatsis.{{200 Kopp,R. 2003}} The EGFR overexpression is 
observed in 30% to 90% of pancreatic cancers, assayed by immunohistochemistry 
techniques.{{201 Faller,B.A. 2009}} The cell membrane EGFR overexpression has been 
demonstrated to be associated with various clinicopathological features. {{187 
Yamanaka,Y. 1992; 188 Yamanaka,Y. 1993; 190 Dong,M. 1998; 183 Uegaki,K. 1997; 
189 Gansauge,F. 1998; 196 Kuniyasu,H. 2001; 195 Tobita,K. 2003; 186 Ueda,S. 2004; 
192 Bloomston,M. 2006; 194 Takikita,M. 2009; 191 Zhang,L. 2002}} However, the 
effect of membrane EGFR overexpression on clinical outcomes is not well defined. The 
association between cytoplasmic expression of EGFR and clinicopathologic features in 
patients with pancreatic cancer has been reported in only one prior study.{{186 Ueda,S. 
2004}} 
 In the current study, we investigated the association between cell membrane and 
cytoplasmic EGFR overexpression and pathologic features in patients with primary 
pancreatic cancer undergoing surgical resection. We also examined the role of EGFR 
overexpression in the prognosis of patients with resected pancreatic cancer. 
 
Methods 
Patients 
Ninety patients who underwent surgical resection for pancreatic cancer at Thomas 
Jefferson University from April 2008 to April 2010 were included in the study. All the 
cases were histologically diagnosed as ductal adenocarcinoma. The patients who did not 
have any event (recurrence or death) were censored at the last date of follow-up. For 
pathologic and immunohistochemical evaluation, 10% neutral-buffered formalin fixed 
and paraffin-embedded tissue blocks from surgically resected specimens were processed 
and 5-µm tissue sections were obtained. The tissue sections were stained using routine 
hemotoxylin and eosin for pathologic diagnosis. The study was approved by Institutional 
review Board at Thomas Jefferson University. 
 
Immunohistochemistry 
Immunohistochemical staining for EGFR was performed on a total of 90 cases 
using the EGFR PharmDxTM kit (Dako). Specimens were evaluated for both cytoplasmic 
and membranous immunostaining by a pathologist blinded to the results at Thomas 
Jefferson University Hospital. Cytoplasmic overexpression was considered positive if 
EGFR expression was noted in the cytoplasm in ≥10% of tumor cells. Cell membrane 
EGFR staining was divided into four categories based on intensity and completeness of 
staining as follows: 0 (no membrane staining or membrane staining in less than 10% of 
tumor cells), 1+ (incomplete membrane staining in ≥ 10% of cells), 2+ (complete, weak 
or moderate membrane staining in ≥ 10% of cells) and 3+ (complete, strong staining in ≥ 
10% of cells) (Figure 1). Scores of 2+ and 3+ were considered membranous EGFR 
overexpression. 
 
Statistical Analysis 
Descriptive statistics were initially used to characterize the cohort. Chi-square test was 
used to determine the association between EGFR overexpression and pathologic features. 
Proportional hazard regression analyses were used to estimate hazard ratios (HR) and 
95% confidence intervals (95% CI). Progression-free survival (PFS) and overall survival 
(OS) was evaluated using Kaplan-Meier survival curves and differences in survival were 
tested using log-rank tests. The two sided p-value of 0.05 was used for statistical 
significance. All statistical analysis was done using SAS statistical software (SAS 
Institute, Inc., Cary, NC). 
 
Results 
Table 1 describes the demographic and pathologic features of the 90 patients of this 
study. The median age of the study cohort was 68 years (Range: 37-92 years). Thirty 
seven (41.1%) patients were female and 53 (58.9%) patients were male. The number of 
patients with AJCC stage I, II, III and IV were 8 (9.2%), 79 (87.8%), 1 (1.1%) and 2 
(2.2%) respectively. Seventy seven patients underwent pylorus-preserving 
pancreaticoduodenectomy and 13 patients underwent distal pancreatectomy. Cell 
membrane EGFR overexpression was observed in 51 (56.7%) patients. Sixty four 
(71.1%) patients had cytoplasmic EGFR overexpression. The relationship between EGFR 
expression and pathologic features is summarized in Table 2. The association between 
cell membrane EGFR overexpression and lymph node positivity was statistically 
significant (p=0.03). No significant association of cell membrane EGFR overexpression 
was found with tumor grade, local invasion, margin positivity, vascular invasion, 
perineural invasion or stage. For cytoplasmic EGFR overexpression, statistically 
significant association was observed with positive margin only (p<0.01). 
The median PFS and OS for the study cohort were 11.8 months and 17.1 months 
respectively. The median follow up time was 15.5 months. Fifty two (58%) patients had 
either recurrence or death during the study follow up. Histological grade, lymphovascular 
invasion and stage were significantly associated with survival. Figure 2 and 3 
demonstrates the Kaplan-Meier PFS and OS curves stratified by membrane EGFR 
overexpression respectively. Membrane EGFR overexpression was associated with 
statistically significant shorter PFS (median PFS: 10.7 vs. 17.0 months, p=0.02). The 
median OS for patients with cell membrane EGFR overexpression was also much shorter 
than the OS in patients without EGFR overexpression (median OS: 15.9 months v 25.3 
months, p=0.08), but this difference was not statistically significant, likely due to the 
small patient numbers (Table 3). For recurrence and death, the HR for patients with cell 
membrane EGFR overexpression (as compared to no EGFR overexpression) was 1.97 
(95% CI: 1.09-3.55) and 1.82 (0.92-3.62) respectively. Cytoplasmic EGFR 
overexpression did not correlate with PFS (median PFS: 11.7 months v 14.4 months, 
p=0.30). The corresponding HR was 1.39 (0.74-2.61) without significant difference in 
survival between patients with or without cytoplasmic EGFR staining (p=0.72). The 
median OS was 17.1 months in patients with cytoplasmic EGFR overepression and 22.6 
months in patients without EGFR overexpression (HR:1.13; 95% CI:0.57-2.27). 
  
Discussion 
 
Few retrospective studies have reported the relationship between EGFR overexpression 
and clinical outcomes in patients with pancreatic cancer.{{187 Yamanaka,Y. 1992; 188 
Yamanaka,Y. 1993; 190 Dong,M. 1998; 183 Uegaki,K. 1997; 189 Gansauge,F. 1998; 
196 Kuniyasu,H. 2001; 195 Tobita,K. 2003; 186 Ueda,S. 2004; 192 Bloomston,M. 2006; 
194 Takikita,M. 2009}} Membrane EGFR overexpression has been demonstrated to be 
associated with higher stage and more aggressive tumors.{{195 Tobita,K. 2003; 191 
Zhang,L. 2002}} However, the effect of EGFR overexpression on recurrence and 
survival in patients with pancreatic cancer remains unclear. Only three out of ten studies 
reported significantly worse survival in patients with membrane EFGR overexpression 
than without it (Table 4).{{187 Yamanaka,Y. 1992; 188 Yamanaka,Y. 1993; 190 
Dong,M. 1998}} In the current study, the resected pancreatic cancer patients with 
membrane EGFR overexpression had worse clinical outcomes. The PFS was significantly 
shorter and there was trend towards poorer survival with membrane EFGR 
overexpression. There was significant association between lymph node involvement and 
membrane EGFR overexpression. 
 
To our knowledge, this is only the second study to evaluate the cytoplasmic EGFR 
overexpression in resected pancreatic cancer patients. In the previous study, patients with 
cytoplasmic EGFR overexpression had shorter overall survival.{{186 Ueda,S. 2004}} 
However, in our study, we did not find any statistically significant difference in 
recurrence or survival in relation to cytoplasmic EGFR overexpression. The cytoplasmic 
staining of EGFR has been demonstrated to be associated with a poor prognosis in 
patients with thyroid carcinoma and lung carcinoma. {{202 Piyathilake,C.J. 2002; 203 
Akslen,L.A. 1993}} EGFR is internalized after the interaction with the ligand and 
completion of growth stimulatory signals and is subsequently degraded in lysosmal 
compartment. Thus, cellular localization pattern of EGFR may be of clinicopathologic 
significance and its role as a prognostic and predictive marker needs to be further 
evaluated. 
  
Membrane EGFR expression is associated with poorer prognosis in head and neck, 
ovarian, cervical, bladder, oesophageal, breast, colorectal and gastric cancers.{{198 
Nicholson,R.I. 2001}} EGFR plays an important role in the growth of various human 
cancers including pancreatic cancer.{{183 Uegaki,K. 1997}} The co-expression of 
EGFR and its ligand may function as an autocrine loop to constantly stimulate cell 
proliferation and blockade of EGFR activity has been shown to decrease the growth and 
metastases of human pancreatic tumor xenografts and enhance the antitumor activity of 
gemcitabine.{{199 Lemoine,N.R. 1992; 204 Bruns,C.J. 2000; 205 Ng,S.S. 2002}} 
Erlotinib, a small molecule EGFR-specific tyrosine kinase inhibitor, has been 
demonstrated to provide modest survival benefit in patients with locally advanced or 
metastatic pancreatic cancer.{{185 Moore,M.J. 2007}} However, cetuximab, a 
monoclonal EGFR antibody did not improve survival in patients with advanced 
pancreatic cancer.{{197 Xiong,H.Q. 2004}} In neither of these studies, did membrane 
EGFR expression predict tumor response to targeted therapy. Cytoplasmic EGFR 
expression was not reported. This suggests that in advanced stage pancreatic cancer 
patients, membrane EGFR expression is not a predictive marker for response to erlotinib 
or cetuximab. The role of both membrane and cytoplasmic EGFR expression in the 
adjuvant setting still needs to be examined.  
 
Despite some recent advances in medical treatment, the prognosis of patients with 
pancreatic cancer remains dismal. Surgery has curative potential but most of the patients 
present with an advanced, unresectable stage. It is important to develop molecular 
markers that can predict clinical outcomes. This may help to direct more aggressive 
approaches in high risk patients. We think that future clinical trials involving EGFR 
inhibitors should incorporate systematic evaluation of both cytoplasmic and membrane 
EGFR expression. 
 
Table 1. Clinicopathologic features of the study population 
Parameter Number (%) 
Age >65 years 51 (56.7) 
Gender  
     Male 53 (58.9) 
     Female 37 (41.1) 
Race  
     White 82 (91.1) 
     Other 8 (8.9) 
Site  
     Head 73 (81.1) 
     Body or/and tail 17 (18.9) 
Grade  
     1 5 (5.6) 
     2 53 (58.9) 
     3 32 (35.6) 
Stage  
     Ia 4 (4.6) 
     Ib 4 (4.6) 
     IIa 16 (17.8) 
     IIb 63 (70.0) 
     III 1 (1.1) 
     IV 2 (2.2) 
Lymph node involvement 64 (71.1) 
Pancreatitis 59 (65.6) 
Cell membrane EGFR overexpression 51 (56.7) 
Cytoplasmic EGFR overexpression 64 (71.1) 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 2. Association between cell membrane and cytoplasmic EGFR overexpression and 
pathologic features. 
Parameter Membrane overexpression Cytoplasmic overexpression 
 Present Absent p Present Absent p 
Local invasion       
          yes 43 31 0.55 52 22 0.70 
          no 8 8  12 4  
Grade 3       
          yes 19 13 0.70 24 8 0.54 
          no 32 26  40 18  
Margin positive       
          yes 17 6 0.05 22 1 <0.01 
          no 34 33  42 25  
Vascular invasion       
          yes 27 18 0.52 30 15 0.35 
          no 24 21  34 11  
Perineural invasion 
          yes 
          no 
 
42 
9 
 
36 
3 
 
0.17 
 
57 
7 
 
21 
5 
 
0.29 
Lymph node       
          yes 41 23 0.03 42 22 0.07 
          no 10 16  22 4  
Stage IIb or higher       
          yes 41 25 0.08 44 22 0.12 
          no 10 14  20 4  
 
p<0.05 is considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 3. Association between EFGR expression and clinical outcomes 
 Progression Free Survival Overall survival 
 Median 
(months) 
HR 95% CI p Median 
(months) 
HR 95% CI p 
Membrane EGFR 
overexpression 
        
     Present 10.7 1.97 1.09-3.55 0.02 15.9 1.82 0.92-3.62 0.08 
     Absent 17.0    25.3    
Cytoplasmic EGFR 
Overexpression 
        
     Present 11.7 1.39 0.74-2.61 0.30 17.1 1.13 0.57-2.27 0.72 
     Absent 14.4    22.6    
p<0.05 is considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Table 4. Membrane EGFR overexpression and survival in patients with pancreatic 
cancer. 
Study Number of 
patients 
EGFR 
overexpression, (%) 
Prognosis 
Yamanka et 
al{{187 
Yamanaka,Y. 
1992; }} 
25 36 Decreased survival 
Yamanka et 
al{{188 
Yamanaka,Y. 
1993; }} 
87 43 Decreased survival 
Dong et 
al{{190 
Dong,M. 1998; 
}} 
57 68 Decreased survival 
Uegaki et 
al{{183 
Uegaki,K. 
1997; }} 
86 44 Trend towards decreased survival 
Gansauge et 
al{{189 
Gansauge,F. 
1998; }} 
82 54 No difference 
Kuniyasi et 
al{{196 
Kuniyasu,H. 
2001; }} 
22 100 No difference 
Tobita et 
al{{195 
Tobita,K. 2003; 
}} 
77 42 No difference 
Ueda et 
al{{186 
Ueda,S. 2004; 
}} 
76 62 No difference 
Bloomston et 
al{{192 
Bloomston,M. 
2006; }} 
71 69 No difference 
Takikita et 
al{{194 
Takikita,M. 
2009; }} 
154 26 No difference 
Current study 90 57 Trend towards decreased survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Representative cases of pancreatic cancer demonstrating scores of membrane 
EFGR expression. A, Score 0; B, Score 1: C, Score 2; D, Score 3. 
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Figure 2. Progression free survival of pancreatic cancer patients stratified by membrane 
EGFR overexpression 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Overall survival of pancreatic cancer patients stratified by membrane EGFR 
overexpression 
 
 
 
 
 
